SWOBY (Swedish Orphan Biovitrum AB) E10: $0.44 (As of Mar. 2026)


SWOBY Swedish Orphan Biovitrum AB SWOBY
67 GF Score
Price $23.18
GF Value $17.17
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB E10?

Swedish Orphan Biovitrum AB SWOBY 67 E10 is $0.44 as of Mar. 2026. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.202. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.44 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Swedish Orphan Biovitrum AB's average E10 Growth Rate was 1.70% per year. During the past 3 years, the average E10 Growth Rate was 12.10% per year. During the past 5 years, the average E10 Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Swedish Orphan Biovitrum AB was 81.70% per year. The lowest was 12.10% per year. And the median was 30.30% per year.

As of today (2026-06-24), Swedish Orphan Biovitrum AB's current stock price is $23.18. Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2026 was $0.44. Swedish Orphan Biovitrum AB's Shiller PE Ratio of today is 52.68.

During the past 13 years, the highest Shiller PE Ratio of Swedish Orphan Biovitrum AB was 545.59. The lowest was 28.96. And the median was 43.74.


Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Swedish Orphan Biovitrum AB's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=23.18/0.44
=52.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Swedish Orphan Biovitrum AB was 545.59. The lowest was 28.96. And the median was 43.74.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Swedish Orphan Biovitrum AB E10 Related Terms


Swedish Orphan Biovitrum AB E10 Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB E10 Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.35 0.34 0.46

Swedish Orphan Biovitrum AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.45 0.44 0.46 0.44

SWOBY vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.


SWOBY
67GF Score
Swedish Orphan Biovitrum AB SWOBY
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.202/133.3862*133.3862
=0.202

Current CPI (Mar. 2026) = 133.3862.

Swedish Orphan Biovitrum AB Quarterly Data

per share eps CPI Adj_EPS
201606 0.066 101.019 0.087
201609 0.028 101.138 0.037
201612 0.015 102.022 0.020
201703 0.040 102.022 0.052
201706 0.054 102.752 0.070
201709 0.072 103.279 0.093
201712 0.075 103.793 0.096
201803 0.110 103.962 0.141
201806 0.137 104.875 0.174
201809 0.123 105.679 0.155
201812 0.116 105.912 0.146
201903 0.160 105.886 0.202
201906 0.086 106.742 0.107
201909 0.090 107.214 0.112
201912 0.233 107.766 0.288
202003 0.193 106.563 0.242
202006 0.049 107.498 0.061
202009 0.050 107.635 0.062
202012 0.287 108.296 0.353
202103 0.130 108.360 0.160
202106 0.051 108.928 0.062
202109 0.088 110.338 0.106
202112 0.220 112.486 0.261
202203 0.091 114.825 0.106
202206 0.041 118.384 0.046
202209 0.065 122.296 0.071
202212 0.214 126.365 0.226
202303 0.162 127.042 0.170
202306 0.033 129.407 0.034
202309 0.014 130.224 0.014
202312 0.146 131.912 0.148
202403 0.112 132.205 0.113
202406 0.031 132.716 0.031
202409 0.206 132.304 0.208
202412 0.183 132.987 0.184
202503 0.124 132.825 0.125
202506 0.096 133.699 0.096
202509 -0.448 133.482 -0.448
202512 0.287 133.386 0.287
202603 0.202 133.386 0.202

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.44 mean?
Swedish Orphan Biovitrum AB (SWOBY) has a E10 of $0.44 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's E10 too high?
Swedish Orphan Biovitrum AB's current E10 is $0.44. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's E10 compare to ZTS?
Swedish Orphan Biovitrum AB's E10 of $0.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current E10 is $0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current E10 is $0.44. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current E10 is $0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for SWOBY:

  • E10: $0.44
  • GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score

Get the complete analysis for SWOBY

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.18
Price
$17.17
GF Value